{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:22:41Z","timestamp":1768868561213,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["801520 HP-JA-2017"],"award-info":[{"award-number":["801520 HP-JA-2017"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["2018\\u2013178"],"award-info":[{"award-number":["2018\\u2013178"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejca.2025.115443","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T15:47:31Z","timestamp":1745077651000},"page":"115443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Estimating cure and risk of death from other causes of adolescent and young adult cancer patients in Europe"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2793-5338","authenticated-orcid":false,"given":"Laura","family":"Botta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Capocaccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Vener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8522-6882","authenticated-orcid":false,"given":"Alice","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Trama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3741-5002","authenticated-orcid":false,"given":"Fabio","family":"Didon\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Demuru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Mohsen","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5832-8410","authenticated-orcid":false,"given":"Frederik","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Bennet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4134-1410","authenticated-orcid":false,"given":"Alexandra","family":"Mayer-da-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Jooste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"40","key":"10.1016\/j.ejca.2025.115443_bib1","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1200\/EDBK_279787","article-title":"Taboo topics in adolescent and young adult oncology: strategies for managing challenging but important conversations central to adolescent and young adult cancer survivorship","author":"Perez","year":"2020","journal-title":"Am Soc Clin Oncol Ed Book"},{"key":"10.1016\/j.ejca.2025.115443_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102203","article-title":"Long-term second primary cancer risk in adolescent and young adult (15-39 years) cancer survivors: a population-based study in the Netherlands between 1989 and 2018","author":"van der Meer","year":"2024","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.ejca.2025.115443_bib3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(19)30800-9","article-title":"Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study","volume":"21","author":"Suh","year":"2020","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2025.115443_bib4","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.3390\/cancers13194870","article-title":"The burden of late effects and related risk factors in adolescent and young adult cancer survivors: a scoping review","volume":"13","author":"Ryder-Burbidge","year":"2021","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.ejca.2025.115443_bib5","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1093\/annonc\/mdr044","article-title":"Late effects in survivors of teenage and young adult cancer: does age matter?","volume":"22","author":"Woodward","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115443_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114187","article-title":"Estimating cure and risk of death from other causes of cancer patients: EUROCARE-6 data on head & neck, colorectal, and breast cancers","volume":"208","author":"Botta","year":"2024","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2025.115443_bib7","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/biostatistics\/kxl030","article-title":"Estimating and modeling the cure fraction in population-based cancer survival analysis","volume":"8","author":"Lambert","year":"2007","journal-title":"Biostatistics"},{"key":"10.1016\/j.ejca.2025.115443_bib8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.canep.2019.02.006","article-title":"French network of Cancer registries (FRANCIM). Time-to-cure and cure proportion in solid cancers in France. A population based study","volume":"60","author":"Romain","year":"2019","journal-title":"Cancer Epidemiol"},{"issue":"5","key":"10.1016\/j.ejca.2025.115443_bib9","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/ije\/dyaa128","article-title":"EUROCARE-5 Working Group. Cancer cure for 32 cancer types: results from the EUROCARE-5 study","volume":"49","author":"Dal Maso","year":"2020","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ejca.2025.115443_bib10","unstructured":"\u3008https:\/\/www.esmo.org\/policy\/right-to-be-forgotten\u3009 (accessed 30 Oct 2024)."},{"key":"10.1016\/j.ejca.2025.115443_bib11","unstructured":"https:\/\/www.iss.it\/en\/eurocare-6 (accessed 4 Oct 2024)."},{"key":"10.1016\/j.ejca.2025.115443_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113558","article-title":"Survival of European adolescents and young adults diagnosed with cancer in 2010-2014","volume":"202","author":"Trama","year":"2024","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2025.115443_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/(SICI)1097-0258(19990228)18:4<441::AID-SIM23>3.0.CO;2-M","article-title":"Mixture models for cancer survival analysis: application to population-based data with covariates","volume":"18","author":"De Angelis","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2025.115443_bib14","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/sim.1101","article-title":"Estimating cancer prevalence using mixture models for cancer survival","volume":"21","author":"Phillips","year":"2001","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.ejca.2025.115443_bib15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12874-023-01876-x","article-title":"A new cure model that corrects for increased risk of non-cancer death: analysis of reliability and robustness, and application to real-life data","volume":"23","author":"Botta","year":"2023","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.ejca.2025.115443_bib16","first-page":"101","article-title":"The relative survival rate: a statistical methodology","volume":"6","author":"Ederer","year":"1961","journal-title":"Nat Cancer Inst Monogr"},{"issue":"13","key":"10.1016\/j.ejca.2025.115443_bib17","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.21.02377","article-title":"Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials","volume":"40","author":"Unger","year":"2022","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2025.115443_bib18","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"GIMEMA. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ejca.2025.115443_bib19","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejca.2025.115443_bib20","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3324\/haematol.2011.045666","article-title":"Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial","volume":"97","author":"Guilhot","year":"2012","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.ejca.2025.115443_bib21","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","article-title":"Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML","volume":"121","author":"Branford","year":"2013","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ejca.2025.115443_bib22","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejca.2025.115443_bib23","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia","volume":"25","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"10.1016\/j.ejca.2025.115443_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27422","article-title":"Temporal trends in the proportion of \"cure\" in children, adolescents, and young adults diagnosed with chronic myeloid leukemia in England: a population-based study","volume":"65","author":"Drozdov","year":"2018","journal-title":"Pedia Blood Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2025.115443_bib25","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.ejca.2008.11.042","article-title":"EUROCARE Working Group. Survival of European children and young adults with cancer diagnosed 1995-2002","volume":"45","author":"Gatta","year":"2009","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2025.115443_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.37245","article-title":"Perceived and objective fertility risk among female survivors of adolescent and young adult cancer","volume":"6","author":"Din","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2025.115443_bib27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12916-024-03488-8","article-title":"Long-term health outcomes by cancer diagnosed age among adolescent and young adult: multinational representative database","volume":"22","author":"Kim","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.ejca.2025.115443_bib28","series-title":"J Adolesc Young Adult Oncol","first-page":"12","article-title":"Psychiatric disorders in adolescent and young adult-onset cancer survivors: a systematic review and meta-analysis","author":"De","year":"2020"},{"issue":"12","key":"10.1016\/j.ejca.2025.115443_bib29","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S1470-2045(22)00637-4","article-title":"EUROCARE-6 working group. long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study","volume":"23","author":"Botta","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2025.115443_bib30","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S1470-2045(24)00312-7","article-title":"Ending financial discrimination for cancer survivors: embedding the Right to be Forgotten in legislation across Europe","volume":"25","author":"Lawler","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:58:26Z","timestamp":1749815906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925002242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":30,"alternative-id":["S0959804925002242"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115443","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimating cure and risk of death from other causes of adolescent and young adult cancer patients in Europe","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115443"}}